

ANTIRETROVIRAL MEDICINES

PRODUCT LIST



HIV/AIDS and antiretroviral medicines

Human immunodeficiency virus (HIV) remains one of the world's greatest public health challenges, particularly in low- and middle-income countries. HIV attacks the body's immune system by targeting CD4 (T) cells, thereby weakening the body's ability to fight infection and disease.

Without treatment, HIV can progress to acquired immunodeficiency syndrome (AIDS) - a stage in which the immune system is severely compromised, leading to life-threatening opportunistic infections and cancers.

Antiretroviral therapy (ART) is the foundation of HIV treatment and prevention. A combination of antiretroviral (ARV) medicines is used to suppress the virus, preserve immune function and prevent onward transmission.

When used consistently, ART enables people living with HIV to live long, healthy lives and significantly reduces the risk of HIV transmission.

Our product range includes WHO-prequalified and WLA-approved ARV formulations for both treatment and prevention:

- First-line, second-line, and paediatric regimens, also available in fixed-dose combinations (FDCs) for simplified dosing along with boosters.

These medicines are categorised according to the WHO's Essential Medicines List (EML) based on their

mechanism of action as nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase inhibitors, FCDs and protease inhibitors.

In addition, some of the above medicines are also added into other important categories, such as:

- Prevention of mother-to-child transmission (PMTCT)
- Post-exposure prophylaxis (PEP) and pre-exposure prophylaxis (PrEP) medicines
- Paediatric formulations
Focusing on low dosage and child friendly formulations such as dispersible tablets, oral solutions and suspensions, granules.

Complementary to these medicines, we offer rapid HIV diagnostic tests and supportive medicines and supplies that might be needed during ARV treatment. You can find all these additional products in the IDA Product Indicator.

We keep stock of some ARV medicines while a lot of medicines and supplies supporting ARV treatment are also available from standard IDA stock.

In the footnotes, we refer to WHO's guidelines, as these consolidated guidelines on HIV are an important step in supporting the goals of universal access to ARV drugs for preventing and treating HIV and ending the HIV/AIDS epidemic as a major public health threat by 2030.

NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTI)

product code	description	abbreviation	unit of measure	
3128-JR1-TG	Abacavir 300mg	ABC	60	tabs
3152-JR1-TD	Abacavir 600mg + Lamivudine 300mg	ABC/3TC	30	tabs
3129-BO1-06	Abacavir 20mg/ml oral solution 240ml	ABC	1	btl
3140-BO1-06	Lamivudine 10mg/ml oral solution 240ml	3TC	1	btl
3107-JR1-TG	Lamivudine 150mg	3TC	60	tabs
3106-JR1-TG	Lamivudine 150mg + Zidovudine 300mg	3TC/AZT	30, 60	tabs
3194-JR1-TD	Lamivudine 300mg + Tenofovir 300mg	3TC/TLC	30	tabs
3132-JR1-TD	Tenofovir Alafnamide 25mg	TAF	30	tabs
3130-JR1-TD	Tenofovir disoproxil fumarate 300mg	TDF	30	tabs
3143-BO1-06	Zidovudine 50mg/5ml oral solution 100ml	ZDV	1	btl
3142-BO1-06	Zidovudine 50mg/5ml oral solution 240ml	ZDV	1	btl

NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTI)

product code	description	abbreviation	unit of measure	
3135-JR1-TD	Efavirenz 600mg	EFV	30	tabs
3193-JR1-TG	Nevirapine 50mg	NVP	60	tabs
3148-BO1-06	Nevirapine 10mg/ml oral suspension 100ml	NVP	1	btl

ANTIRETROVIRAL MEDICINES

PRODUCT LIST



INTEGRASE INHIBITOR

product code	description	abbreviation	unit of measure	
3198-JR1-TE	Dolutegravir 10 mg dispersable/scored	DTG	90	tabs
3197-JR1-TD	Dolutegravir 50mg	DTG	30	tabs

FIXED DOSE COMBINATIONS OF ANTI-RETROVIRAL

product code	description	abbreviation	unit of measure	
3153-JR1-TD	Abacavir 120 mg+ Lamivudine 60mg disp tab	ABC/3TC	30,6	tabs
3159-JR1-TE	Abacavir 60mg +Dolutegravir 5mg + lamivudine 30mg dispersible tablet ^A	ABC/DTG/3TC	90, 180	tabs
	Abacavir 600mg + Dolutegravir 50mg + Lamivudine 300mg ^A	ABC/DTG/3TC	30	tabs
3191-JR1-TD	Dolutegravir 50mg + Emtricitabine 200mg + Tenofovir Alafenamide 25mg ^A	DTG/FTC/TAF	30, 90	tabs
3134-JR1-TD	Efavirenz 600mg + Emtricitabine 200mg + Tenofovir 300mg ^A	EFV/FTC/TDF	30	tabs
3184-JR1-TD	Efavirenz 600mg + Lamivudine 300mg + Tenofovir 300mg ^A	EFV/3TC/TDF	30	tabs
3187-JR1-TG	Lamivudine 30mg + Zidovudine 60mg dispersible	3TC/AZT	60	tabs
3131-JR1-TD	Tenofovir 300mg + Emtricitabine 200mg	TDF/FTC	30	tabs
3183-JR1-TD	Tenofovir 300mg + Lamivudine 30mg + Efavirenz 400mg ^A	TDF/3TC/EFV	30	tabs
3194-JR1-TD	Tenofovir DF 300mg + Lamivudine 300mg + Dolutegravir 50mg ^A	TDF/3TC/DTG	30, 90, 180	tabs

^A - Preferred first line ART regimens

PAEDIATRIC FORMULATIONS

product code	description	abbreviation	unit of measure	
3128-JR1-TG	Abacavir 300mg	ABC	60	tabs
3159-JR1-TE	Abacavir 60mg + Dolutegravir 5mg + Lamivudine 30mg dispersible tablet	ABC/DTG/3TC	90, 180	tabs
3153-JR1-TD	Abacavir 120mg + Lamivudine 60mg dispersible tablet	ABC/3TC	30, 60	tabs
3129-BO1-06	Abacavir 20mg/ml oral solution 240ml	ABC	1	btl
3198-JR1-TE	Dolutegravir 10mg dispersable/scored	DTG	90	tabs
3140-BO1-06	Lamivudine 10mg/ml oral solution 240ml	3TC	1	btl
3187-JR1-TG	Lamivudine 30mg + Zidovudine 60mg dispersible	3TC/AZT	60	tabs
3167-SA1-BK	Lopinavir 40mg + Ritonavir 10mg oral granules	LPV/r	120	sacs
3141-BO1-J4	Lopinavir 80mg/ml + Ritonavir 20mg/ml oral solution 60ml	LPV/r	5	btls
3148-BO1-06	Nevirapine 10mg/ml oral suspension 100ml	NVP	1	btl
3143-BO1-06	Zidovudine 50mg/5ml oral solution 100ml	ZDV	1	btl
3142-BO1-06	Zidovudine 50mg/5ml oral solution 240ml	ZDV	1	btl

PROTEASE INHIBITORS

product code	description	abbreviation	unit of measure	
3179-JR1-TD	Atazanavir 300mg + Ritonavir 100mg ^B	ATV/r	30	tabs
3189-JR1-TG	Darunavir 600mg	DRV	30, 60	tabs
3171-JR1-TG	Lopinavir 100mg + Ritonavir 25mg ^B	LPV/r	60, 120	tabs
3170-JR1-TI	Lopinavir 200mg + Ritonavir 50mg ^B	LPV/r	120	tabs
3167-SA1-BK	Lopinavir 40mg + Ritonavir 10mg oral granules	LPV/r	120	sacs
3141-BO1-J4	Lopinavir 80mg/ml + Ritonavir 20mg/ml oral solution 60ml	LPV/r	5	btls
3188-JR1-TD	Ritonavir 100mg	RTV	30, 60	tabs

^B - Second line ART regimens: Include boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs). Common bPIs include lopinavir/ritonavir (LPV/r) and atazanavir/ritonavir (ATV/r). Dolutegravir (DTG) is also a recommended option for second-line therapy.

ANTIRETROVIRAL MEDICINES

PRODUCT LIST



PREVENTION OF MOTHER-TO-CHILD TRANSMISSION (PMTCT) ^c

product code	description	abbreviation	unit of measure	
3135-JR1-TD	Efavirenz 600mg	EFV	30	tabs
3149-JR1-TD	Lamivudine 300mg + Tenofovir DF 300mg	3TC/TDF	30	tabs
3171-JR1-TG	Lopinavir 100mg + Ritonavir 25mg	LPV/r	60, 120	tabs
3170-JR1-TI	Lopinavir 200mg + Ritonavir 50mg	LPV/r	120	tabs
3148-BO1-06	Nevirapine 10mg/ml oral suspension 100ml	NVP	1	btl
3193-JR1-TG	Nevirapine 50mg tablets for oral suspension	NVP	60	tabs
3183-JR1-TD	Tenofovir 300mg + Lamivudine 300mg + Efavirenz 400mg	TDF/3TC/EFV	30	tabs
3130-JR1-TD	Tenofovir disoproxil fumarate 300mg	TDF	30	tabs
3194-JR1-TD	Tenofovir DF 300mg + Lamivudine 300mg + Dolutegravir 50 mg ^A	TDF/3TC/DTG	30, 90, 180	tabs
3143-BO1-06	Zidovudine 50mg/5ml oral solution 100ml	ZDV	1	btl
3142-BO1-06	Zidovudine 50mg/5ml oral solution 240ml	ZDV	1	btl

^c - PMTCT is a combination of antiretroviral therapy (ART) for the mother and a short-course ARV regimen for the baby. Pregnant women living with HIV should ideally be on a three-drug ART regimen throughout their pregnancy to suppress viral load. This significantly reduces the risk of transmission to the baby

MEDICATION FOR PRE-EXPOSURE PROPHYLAXIS (PREP) AND POST-EXPOSURE PROPHYLAXIS (PEP)

product code	description	abbreviation	unit of measure	
	Abacavir 600mg + Dolutegravir 50mg + Lamivudine 300mg ^A	ABC/DTG/3TC	30	tabs
3152-JR1-TD	Abacavir 600mg + Lamivudine 300 mg	ABC/3TC	30	tabs
3106-JR1-TG	Lamivudine 150mg + Zidovudine 300mg	3TC/AZT	30, 60	tabs
3149-JR1-TD	Lamivudine 300mg + Tenofovir DF 300mg	3TC/TDF	30	tabs
3149-JR1-TD	Lamivudine 300mg + Tenofovir DF 300mg	3TC/TDF	30	tabs
3171-JR1-TG	Lopinavir 100mg + Ritonavir 25mg	LPV/r	60, 120	tabs
3170-JR1-TI	Lopinavir 200mg + Ritonavir 50mg	LPV/r	120	tabs
3131-JR1-TD	Tenofovir 300mg + Emtricitabine 200mg	TDF/FTC	30	tabs
3183-JR1-TD	Tenofovir 300mg + Lamivudine 300mg + Efavirenz 400mg	TDF/3TC/EFV	30	tabs
3194-JR1-TD	Tenofovir DF 300mg + Lamivudine 300mg + Dolutegravir 50mg	TDF/3TC/DTG	30, 90, 180	tabs

POST-EXPOSURE PROPHYLAXIS (PEP) PEP KIT AS PART OF IEHK 2024 EMERGENCY HEALTH KIT

product code	description	unit of measure	
A159-000-02	(IEHK 2024 SUPPLEMENTARY) UNIT , MEDICINE, PEP (2.7)	1	kit

References

- <https://iris.who.int/bitstream/handle/10665/371090/WHO-MHP-HPS-EML-2023.02-eng.pdf?sequence=1>
- <https://iris.who.int/bitstream/handle/10665/325892/WHO-CDS-HIV-19.15-eng.pdf?sequence=1>
- <https://www.hiv.gov/hiv-basics/hiv-prevention/using-hiv-medication-to-reduce-risk/pre-exposure-prophylaxis>
- <https://extranet.who.int/prequal/medicines/prequalified/finished-pharmaceutical-products>